The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Sonali M. Smith, Heiko Schöder, Jeffrey L. Johnson, Sin Ho Jung, Nancy L. Bartlett, Bruce D. Cheson

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed-Sternberg cells. Galiximab is a primatized monoclonal antibody against CD80, with a favorable toxicity profile demonstrated in other lymphomas. Cancer and Leukemia Group B (CALGB) 50602 (Alliance) tested single-agent galiximab in a highly refractory group of patients with Hodgkin lymphoma (median 3 prior regimens, 83% failing after prior stem cell transplant) to determine the efficacy. The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hodgkin lymphoma.

Original languageEnglish
Pages (from-to)1405-1410
Number of pages6
JournalLeukemia and Lymphoma
Volume54
Issue number7
DOIs
StatePublished - Jul 2013

Keywords

  • CD80
  • Clinical trial
  • Galiximab
  • Hodgkin lymphoma

Fingerprint

Dive into the research topics of 'The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)'. Together they form a unique fingerprint.

Cite this